# Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients

> **NCT01031628** · PHASE3 · TERMINATED · sponsor: **Sarcoma Alliance for Research through Collaboration** · enrollment: 5 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Imatinib mesylate
- **DRUG:** Imatinib mesylate
- **DRUG:** Imatinib mesylate

## Key facts

- **NCT ID:** NCT01031628
- **Lead sponsor:** Sarcoma Alliance for Research through Collaboration
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Lack of feasibility secondary to slow accrual
- **Last updated:** 2013-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01031628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01031628, "Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01031628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*